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Objective: C-reactive protein (CRP) is an independent risk factor for coronary artery disease (CAD).
Metabolic syndrome has been associated with an increased risk of CAD, as well as increased mortality
from CAD. The aim of this study is to investigate the relationship between CRP and metabolic syndrome
among CAD patients.
Materials and Methods: Fasting blood samples were obtained from 112 CAD patients. Metabolic syndrome
and its components were deﬁned using the diagnostic criteria from the International Diabetes
Federation.
Results: Using Taiwanese individuals, a total of 56 CAD patients (50%) had metabolic syndrome. Fasting
CRP levels positively correlated with metabolic syndrome (p ¼ 0.014). Univariate linear regression
analysis showed that body weight (p ¼ 0.014), body mass index (p < 0.001), and body fat mass
(p < 0.001) were positively correlated with serum CRP levels, while high-density lipoprotein cholesterol
(HDL-C) (p ¼ 0.049) was negatively correlated with fasting serum CRP levels in CAD patients. Multi-
variate forward stepwise linear regression analysis of the signiﬁcant variables showed that body fat mass
(b ¼ 0.530, R square ¼ 0.289, p < 0.001) and HDL-C (b ¼ 0.171, R square ¼ 0.029, p ¼ 0.034) were
independent predictors of serum CRP levels in CAD patients.
Conclusion: CRP level positively correlated with metabolic syndrome among Taiwanese CAD patients.
Body fat mass and HDL-C were independent predictors of serum CRP levels in CAD patients.
Copyright  2011, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC.
All rights reserved.1. Introduction
C-reactive protein (CRP) is a hepatic derived pentraxin that plays
a key role in the innate immune response and is an independent
risk factor for coronary artery disease (CAD) [1,2]. Metabolic
syndrome is a signiﬁcant risk factor for cardiovascular disease and
mortality in the general population [3,4]. It is also independently
associated with CAD [5]. CAD patients with metabolic syndrome
show an increased risk of cardiovascular morbidity after follow-up
[6]. Recent studies have shown that a high level of CRP is associated
withmetabolic syndrome among European individuals [7]. The aim
of this study was to investigate the relationship between serum
CRP level and the metabolic syndrome among CAD patients in
Taiwan.y, Buddhist Tzu Chi General
aiwan. Tel.: þ886 3 8561825;
. Wang).
ddhist Compassion Relief Tzu Chi2. Materials and methods
2.1. Patients
Between June 2008 and December 2008, 112 CAD consecutive
clinic outpatients at a medical center in Hualien, eastern Taiwan
(80 males and 32 females), who were deﬁned as individuals having
as > 50% stenosis in any segment by coronary angiography, were
enrolled into this study. The Protection of Human Subjects Insti-
tutional Review Board of Tzu Chi University and Hospital approved
this study. Patients were excluded if they had any acute infection,
acute myocardial infarction, acute coronary syndrome, pulmonary
edema, heart failure at the time of blood sampling or if they refused
to provide informed consent for the study.
2.2. Anthropometric analysis
Body weight was measured in light clothing and without shoes
to the nearest half kilogram. Height was measured to the nearestFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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half centimeter at the shortest point below the lower rib margin
and the iliac crest. The body mass index (BMI) was calculated as
weight (kilograms) divided by height squared (meters). Bio-
impedance measurements of fat mass were performed at the
bedside, using the standard tetrapolar whole body (hand-foot)
technique and a single-frequency (50 kHz) analyzer (Biodynamic-
450, Biodynamics Corporation, Seattle, WA, USA). Measurements
were carried out by the same operator and the fat mass was
analyzed using the speciﬁc formulae provided by the manufac-
turer [8].
2.3. Biochemical investigations
Fasting blood samples taken from each subject were immedi-
ately centrifuged at 3000 g for 10 minutes for the biochemical
studies. The serum was stored at 4C for biochemical examination
within 1 hour after collection. Serum levels of creatinine (Cre),
fasting glucose, total cholesterol (TCH), triglyceride (TG), high-
density lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C), albumin, globulin, and C-reactive protein (CRP)
were measured using an autoanalyzer (COBAS Integra 800, Roche
Diagnostics, Basel, Switzerland).
2.4. Metabolic syndrome and its components
The prevalence of metabolic syndrome was deﬁned using the
International Diabetes Federation deﬁnition [9]. People were
classiﬁed as having metabolic syndrome if they had central
(abdominal) obesity with a waist circumference 90 cm (men) or
80 cm (women) (Chinese criteria), and had two or more of the
following additional criteria: fasting serum glucose 110 mg/dL,
triglycerides 150 mg/dL, HDL-C level <40 mg/dL in men or
<50 mg/dL in women, or blood pressure 130/85 mm Hg. The use
of antihypertensive medication was considered as equivalent to
high blood pressure in this analysis. Type 2 diabetes was deter-
mined according to World Health Organization criteria [10]. A
person was regarded as diabetic if either the fasting plasma
glucose 126 mg/dL, or the 2 hour glucose during an oral glucose
tolerance test was 200 mg/dL, or if he/she was using diabetes
medication (oral or insulin).
2.5. Statistical analysis
Data are expressed as means  standard deviation (SD) and
tested for normal distribution by Kolmogorov-Smirnov statistics.
Categorical variables were analyzed by the Chi-square test.Table 1
Clinical and analytical characteristics of 112 coronary artery disease patients.
Item Parameter
Anthropometric ﬁndings Height (cm) 160.3
Body weight (kg) 67.65
Body mass index (kg/m2) 25.84
Gender (male/female) 80/32
Biochemical ﬁndings Albumin (g/dL) 4.42 
Triglyceride (mg/dL) 145.0
Fasting glucose (mg/dL) 122.6
CRP (mg/dL) 0.39 
Creatinine (mg/dL) 1.15 
Data are expressed as means  SDs or proportion.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CCB ¼ calc
cholesterol; LDL-C ¼ low-density lipoprotein cholesterol.Comparisons between patients were performed using the Student
t test (two tailed) for normally distributed data, or the Mann-
Whitney U test for parameters that presented with non-normal
distribution (fasting glucose, CRP, and Cre). Clinical variables that
correlated with CRP in CAD patients were evaluated by univariate
linear regression analyses. Variables that were signiﬁcantly asso-
ciated with CRP in CAD patients were tested for independency by
multivariate forward stepwise regression analysis. Data were
analyzed using SPSS for Windows (version 13.0; SPSS Inc., Chicago,
IL, USA). A p value <0.05 was considered statistically signiﬁcant.3. Results
The clinical and laboratory characteristics of the CAD patients
are presented in Table 1 and Table 2. Medical histories included:
diabetes (n ¼ 43; 36.7%), hypertension (n ¼ 90; 80.4%), and
hyperlipidemia (n ¼ 71; 63.4%). The use of drugs included: angio-
tensin receptor blocker (ARB; n ¼ 39; 34.8%), angiotensin-
converting enzyme inhibitor (ACEI; n ¼ 33; 29.5%), calcium
channel blocker (CCB; n ¼ 24; 21.4%), b-blocker (n ¼ 64; 57.1%),
thiazide (n ¼ 29; 25.9%), ﬁbrate (n ¼ 8; 7.1%), aspirin (n ¼ 68;
60.7%), clopidogrel (n ¼ 35; 31.3%), sulfonylurea (n ¼ 24; 21.4%),
metformin (n ¼ 22; 19.6%), peroxisome proliferator-activated
receptor-g (PPAR-g) agonist (n¼ 5; 4.5%) and statin (n¼ 65; 58.0%).
The clinical characteristics and fasting serum CRP levels of the
112 CAD patients are presented in Table 2. A total of 56 patients
(50.0%) had metabolic syndrome. CAD patients with metabolic
syndrome had a higher CRP level (p ¼ 0.014). CRP levels did not
differ statistically by gender distribution, diabetes, hypertension,
hyperlipidemia, ARB, ACEI or CCB. Neither did they differ by b-
blocker, thiazide, statin, ﬁbrate, sulfonylurea, metformin or PPAR-g
drugs use. Multivariate forward stepwise linear regression analysis
of the clinical characteristics and fasting serum CRP levels also
showed that metabolic syndrome (b ¼ 0.334, R square ¼ 0.112,
p < 0.001) was positively correlated with serum CRP levels in CAD
patients (data not shown).
The univariate linear analysis of fasting serum CRP levels in CAD
patients is presented in Table 3. Body weight (p¼ 0.014), bodymass
index (p < 0.001), and body fat mass (p < 0.001) were positively
correlated with serum CRP levels, while HDL-C (p ¼ 0.049) was
negatively correlatedwith fasting serum CRP levels in CAD patients.
Multivariate forward stepwise linear regression analysis of the
signiﬁcant variables showed that body fat mass (b ¼ 0.530, R
square¼ 0.289, p< 0.001) and HDL-C (b¼e0.171, R square¼ 0.029,
p ¼ 0.034) were the independent predictors of serum CRP levels in
CAD patients (Table 4).Parameter
4  15.68 Waist circumference (cm) 91.47  9.80
 11.23 Body fat mass (%) 27.95  6.83
 3.58 Age (y) 68.37  11.33
0.34 Globulin (g/dL) 3.08  0.43
0  70.93 Total cholesterol (mg/dL) 167.05  35.55
2  44.35 HDL-C (mg/dL) 46.43  12.44
0.39 LDL-C (mg/dL) 105.63  31.57
0.97
ium channel blocker; CRP ¼ C-reactive protein; HDL-C ¼ high-density lipoprotein
Table 4
Multivariate stepwise linear regression analysis of body weight, body mass index,
body fat mass, and HDL-C level: correlation with fasting serum C-reactive protein
levels in the 112 coronary artery disease patients.
Items Beta R square R square
change
p
Body fat mass (%) 0.530 0.289 0.289 <0.001*
HDL-C (mg/dL) 0.171 0.318 0.029 0.034*
*p < 0.05 was considered statistically signiﬁcant in the multivariate stepwise linear
regression analysis.
HDL-C ¼ high-density lipoprotein cholesterol.
Table 2
Clinical characteristics and fasting serum C-reactive protein levels of 112 coronary
artery disease patients.
Characteristic Number (%) CRP (mg/dL) p
Gender Male 80 (71.4) 0.38  0.36 0.819
Female 32 (28.6) 0.40  0.41
Diabetes No 69 (61.6) 0.39  0.36 0.713
Yes 43 (38.4) 0.40  0.44
Hypertension No 22 (19.6) 0.31  0.23 0.886
Yes 90 (80.4) 0.41  0.42
Hyperlipidemia No 41 (36.6) 0.42  0.40 0.625
Yes 71 (63.4) 0.38  0.39
Metabolic syndrome No 56 (50.0) 0.26  0.21 0.014*
Yes 56 (50.0) 0.52  0.48
ARB No 73 (65.2) 0.35  0.36 0.127
Yes 39 (34.8) 0.47  0.44
ACE inhibitors No 79 (70.5) 0.42  0.41 0.202
Yes 33 (29.5) 0.33  0.32
CCB No 88 (78.6) 0.36  0.38 0.073
Yes 24 (21.4) 0.52  0.42
b-blocker No 48 (42.9) 0.35  0.37 0.171
Yes 64 (57.1) 0.43  0.40
Thiazide No 83 (74.1) 0.39  0.34 0.269
Yes 29 (25.9) 0.41  0.38
Statin No 47 (42.0) 0.41  0.38 0.269
Yes 65 (58.0) 0.38  0.40
Fibrate No 104 (92.9) 0.39  0.39 0.968
Yes 8 (7.1) 0.38  0.37
Sulfonylurea No 88 (78.6) 0.40  0.39 0.498
Yes 24 (21.4) 0.38  0.41
Metformin No 90 (80.4) 0.41  0.39 0.201
Yes 22 (19.6) 0.33  0.39
PPAR-g agonist No 107 (95.5) 0.40  0.40 0.257
Yes 5 (4.5) 0.18  0.10
*p < 0.05 was considered statistically signiﬁcant after performing the Mann-
Whitney U test.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker;
CCB ¼ calcium channel blocker; PPAR-g ¼ peroxisome proliferator-activated
receptor-g.
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The results of our study showed that the CRP level was posi-
tively associated with metabolic syndrome in CAD patients. Body
fat mass and HDL-C were the independent predictors of serum CRP
levels in CAD patients. Metabolic syndrome is a constellation of
physical and laboratory abnormalities including hypertension,
hyperglycemia, hyperlipidemia, and abdominal obesity [9]. Meta-
bolic syndrome constitutes amajor health problem in theWest, andTable 3
Correlation between fasting serum C-reactive protein levels and clinical variables in
112 coronary artery disease patients by univariate linear regression analyses.
Items Beta p
Age (y) 0.057 0.430
Height (cm) 0.124 0.191
Body weight (kg) 0.232 0.014*
Waist circumference (cm) 0.164 0.084
Body mass index (BMI; kg/m2) 0.396 <0.001*
Body fat mass (%) 0.537 <0.001*
Albumin (g/dL) 0.054 0.568
Globulin (g/dL) 0.062 0.517
Total cholesterol (mg/dL) 0.021 0.828
Triglyceride (mg/dL) 0.118 0.217
HDL-C (mg/dL) 0.187 0.049*
LDL-C (mg/dL) 0.012 0.904
Fasting glucose (mg/dL) 0.178 0.060
Creatinine (mg/dL) 0.041 0.667
*p < 0.05 was considered statistically signiﬁcant after univariate linear analyses.
HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein
cholesterol.is estimated to affect at least 20% of the adult population [11].
Recent studies have also demonstrated that metabolic syndrome is
a signiﬁcant risk factor for cardiovascular disease and mortality in
the general population [3,4]. The overall prevalence of the meta-
bolic syndrome in CAD patients has been found to be between
37.5% and 65.5% by various studies [2,6,12,13]. The prevalence of
metabolic syndrome in our study was 50%, which is a similar
prevalence to that reported by other studies of CAD patients [6,13].
CRP is an acute phase marker whose blood levels depend on
interleukin-6 and other inﬂammatory proteins that stimulate its
production by hepatocytes, lymphocytes, alveolarmacrophages and
monocyte-derived macrophages in atherosclerotic plaques [14].
CRP can induce a number of activities at tissue and cell levels
involved in the processes of atherosclerosis and thrombosis [15].
CRP has been shown to impair insulin signalling, contribute to
atherothrombosis, and is associated with insulin resistance,
adiposity and metabolic syndrome [16]. Beyond traditional estab-
lished cardiovascular risk factors, CRP has been shown to be crucial
throughout atherosclerosis from endothelial dysfunction to plaque
rupture and thrombosis [17]. Recent studies have found that CRP is
an independent risk factor for CAD [1,2]. High CRP levels have been
related to the risk factors for dyslipidemia, hypertension, diabetes
mellitus, and obesity [18]. CRP interacted multiplicatively with
apolipoprotein B and other variables associated with metabolic
syndrome [19]. Elevated CRP levels have been associated with
metabolic syndrome among European individuals [7]. In a similar
ﬁnding for Taiwanese individuals, our study noted that CADpatients
with metabolic syndrome had higher fasting serum CRP levels.
CRP concentration was found to be positively correlated with
body weight, negatively correlated with fasting concentration of
triglycerides and showed no correlation with LDL-C or total
cholesterol in a Czech population [20]. CRP concentration has been
directly related to the volume of visceral fat determined by
magnetic resonance imaging [21]. Abdominal adiposity resulted in
signiﬁcantly elevated CRP values among non-obese people [22]. A
higher BMI, as well as central obesity, have been shown to be
independently associated with higher levels of CRP in Taiwan [23].
Higher amounts of visceral adipose tissue have been associated
with CRP and this may lead to subclinical left ventricular diastolic
dysfunction in otherwise-healthy subjects [24]. Higher CRP levels
were also observed in subjects with a high BMI and a high waist
circumference among European CAD patients [7]. However, one
study noted that, in the lower tertile of BMI, patients with CAD had
a markedly higher CRP concentration compared to control subjects
[25]. Our study found that, among CAD patients, body weight, BMI,
and body fat masswere positively correlatedwith the fasting serum
CRP levels, while HDL-C was negatively correlated with the fasting
serum CRP levels. CRP concentrationwas not correlated with LDL-C
level, waist circumference, triglyceride level, fasting glucose level
or total cholesterol level in our study. The multivariate forward
stepwise linear regression analysis of the signiﬁcant variables
showed that body fat mass and HDL-C were independent predic-
tors of fasting serum CRP levels in our study. Further studies are
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syndrome components in CAD patients.
Pharmacological interventions have been shown to inﬂuence
serum CRP levels in humans. Statins can reduce serum CRP level,
independent of the type and dose of statin used [26]. PPAR-a acti-
vation by ﬁbrates also impairs pro-inﬂammatory cytokine-
signaling pathways in the liver resulting in modulation of the acute
phase response reaction via mechanisms independent of changes
in lipoprotein levels [27]. PPAR-g agonist treatment results in
decreased plasma levels of CRP in both obese and type 2 diabetic
patients [28]. In hypertension patients, b-blocker, angiotensin-
converting enzyme inhibitor and angiotensin receptor blocker
monotherapy have been associated with lower CRP levels than in
those taking a diuretic monotherapy [29]. Our results did not show
a relationship between the use of statins, PPAR-g agonists or other
drugs (ARB, ACEI, CCB, ﬁbrate or thiazide diuretic) and serum CRP
among our CAD patients.
There are some limitations to our study. Firstly, this study is
a cross-sectional design. Therefore, our ﬁndings need to be further
investigated using long-term prospective studies before a causal
relationship between serum CRP and metabolic syndrome in CAD
patients can be established. Secondly, serum insulin or insulin
resistance were not measured in this study. Thirdly, there is no
control group in the study. Another limitation is that this study did
not check other inﬂammatory markers, such as TNF-a, IL-6, and IL-
12. Finally, the sample size is small and the power of this study is
only 0.75 (analysis by G-Power 3.0.1), so more patients are needed
to support our ﬁndings. Therefore, further studies are also needed
to investigate the association of metabolic syndrome and serum
CRP levels in patients with or without CAD.
In summary, we found a positive association between circu-
lating fasting CRP levels and metabolic syndrome among CAD
patients. Body fat mass and HDL-C were the independent predic-
tors of serum CRP levels among Taiwanese CAD patients.Acknowledgement
This study was supported by a grant from Buddhist Tzu Chi
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